| JAK2 V617F基因突变阳性骨髓增殖性肿瘤治疗研究进展 |
| |
| 引用本文： | 林凤茹,王艳,张敬宇. JAK2 V617F基因突变阳性骨髓增殖性肿瘤治疗研究进展[J]. 白血病．淋巴瘤, 2015, 0(7): 392-393. DOI: 10.3760/cma.j.issn.1009-9921.2015.07.003 |
| |
| 作者姓名： | 林凤茹 王艳 张敬宇 |
| |
| 作者单位： | 河北医科大学第二医院血液科, 石家庄,050000 |
| |
| 摘 要： | JAK2 V617F基因突变阳性骨髓增殖性肿瘤(MPN)由真性红细胞增多症(PV)、原发性血小板增多症(ET)和原发性骨髓纤维化(PMF)组成.文章聚焦于其危险度积分系统和治疗进展,包括一线及二线治疗、JAK2抑制剂、降细胞治疗、抗纤维化和其他单药或联合治疗.
|
| 关 键 词： | 骨髓增殖性肿瘤 JAK2 V617F基因突变 治疗 |
Advances in the treatment of JAK2 V617F gene mutation positive myeloproliferative neoplasms |
| |
| Abstract: | JAK2 V617F gene mutation positive myeloproliferative neoplasms (MPN) consists of polycythemia vera (PV),essential thrombocythemia (ET) and primary myelofibrosis (PMF).This article focuses on their risk scoring systems and treatment including first-and second-line therapies,JAK2 inhibitors,cytoreduction,antifibrosis and other single-agent or combination therapy. |
| |
| Keywords: | Myeloproliferative neoplasms JAK2 V617F gene mutation Therapy |
| 本文献已被 万方数据 等数据库收录！ |
